Polyvascular disease and risk: When two is not better than one
Open Access
- 20 September 2018
- journal article
- editorial
- Published by SAGE Publications in Vascular Medicine
- Vol. 23 (6), 531-533
- https://doi.org/10.1177/1358863x18796936
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trialVascular Medicine, 2018
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery DiseaseCirculation, 2018
- Rivaroxaban with or without Aspirin in Stable Cardiovascular DiseaseThe New England Journal of Medicine, 2017
- Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial DiseaseJAMA Cardiology, 2016
- Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial InfarctionCirculation, 2016
- Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery DiseaseJournal of the American College of Cardiology, 2016
- Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trialThe Lancet, 2013
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesThe New England Journal of Medicine, 2009
- Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromesEuropean Heart Journal, 2009